在巨细胞动脉炎中持续无药缓解
Javier Narváez1, Marta Domínguez2, Eva Galíndez3
1Department of Rheumatology, Hospital Universitario de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Rheumatology (Oxford, England)
|November 26, 2024
概括
大约四分之一的巨细胞动脉炎 (GCA) 患者在3-4年内实现了持续无药缓解 (SDFR). 复发和初始IV甲基普雷迪尼索隆使用预测了更长的葡萄皮质类药物需求.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 巨细胞动脉炎 (GCA) 是一种系统性血管炎,影响大动脉.
- 长期的葡萄糖皮质激素治疗是标准的,但与显著的副作用有关.
- 确定持续无药缓解 (SDFR) 的预测因素对于优化GCA管理至关重要.
研究的目的:
- 为了确定GCA患者SDFR的频率和时间.
- 确定预测实现SDFR的因素.
- 在实现SDFR后评估复发的风险.
主要方法:
- 来自西班牙多中心注册局 (ARTESER) 的872名GCA患者的回顾性审查.
- 最低2年的随访时间.
- SDFR定义为在停止治疗后≥12个月没有GCA活性.
主要成果:
- 在4年内,在21.2%的患者中实现了SDFR.
- 累计的SDFR率为6.3% (2年),20.5% (3年) 和25.3% (4年).
- 在诊断时复发和需要IV甲基普雷迪尼索隆预测SDFR的可能性较低.
- 复发率很低 (2.7%),SDFR后的中位数发病时间为19个月.
结论:
- 大约四分之一的GCA患者在3-4年内达到SDFR.
- SDFR与更快的普德尼松减少和更少的复发有关.
- 复发和最初的IV甲基前尼索隆胆固醇是长期葡萄糖皮质类药物依赖的预测因素.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K